We enter 2025 with strong momentum and a clear focus on realizing the company’s strategic goals. Our pivotal migraine study was recently published in the leading medical journal Neurology, marking a scientific breakthrough that strengthens Ozilia’s role in migraine care and our global potential. At the same time, in October 2024, we took a significant step forward in our strategy by initiating an exit process with the support of an international advisor. The goal is to identify a global player who can integrate our technology into their product portfolio, maximizing value for both the company and our shareholders. The publication in Neurology and recent breakthroughs in two of our key markets, Switzerland and Saudi Arabia, underscore both the strength of our technology and our commercial potential.
In Switzerland, the establishment of our technology began last summer through an agreement with a national distributor, along with an initial order. In Saudi Arabia, we have obtained key market approvals for the migraine indication, opening the door for sales and broader commercialization in a region with a significant need for innovative treatment options. These advances, along with developments in our other key markets, confirm that Ozilia is meeting a global need and has the potential to become an essential part of the future of migraine care.
The Board’s decision to initiate the exit process is based on our long-communicated strategic assumption that our technology can generate greater value in the hands of an established player with global reach. We see this as a unique opportunity to maximize the potential of our technology and create strong returns for our shareholders.
During 2025, we will focus exclusively on activities that, including the PM009 and PM010 studies, further strengthen the exit process and value creation. At the same time, we are actively working to ensure that our technology reaches more patients and reinforces our position in the markets where we operate, aiming to demonstrate proof-of-concept in the market.
I look forward to the decisive year of 2025 with great confidence. With our scientific legitimacy, regulatory successes, and a clearly defined strategy, we are well-positioned to execute the exit phase of the company’s long-term plan.
Thank you for your continued support and trust.
Anders Weilandt, CEO Chordate Medical
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia®, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31
Delivery: Hanstavägen 31, 164 53 Kista
